{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "DNA methylation",
      "chromatin remodeling",
      "early life stress",
      "histone modification",
      "noncoding RNA"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "La depresi\u00f3n es un trastorno psiqui\u00e1trico devastador causado por una combinaci\u00f3n de una predisposici\u00f3n gen\u00e9tica y de acontecimientos vitales, en que destaca la exposici\u00f3n al estr\u00e9s. Se sabe que el estr\u00e9s en los inicios de la vida (EIV) deja una \u201ccicatriz\u201d en el cerebro, lo que lleva a un aumento de la susceptibilidad para desarrollar una depresi\u00f3n en a\u00f1os posteriores a trav\u00e9s de mecanismos epigen\u00e9ticos. Los procesos epigen\u00e9ticos conducen a cambios en la expresi\u00f3n g\u00e9nica que no se deben a cambios en la secuencia de ADN, sino que ocurren mediante la modulaci\u00f3n de las modificaciones de la cromatina, de la metilaci\u00f3n del ADN y de los ARNs no codificantes. En este art\u00edculo se revisan los mecanismos epigen\u00e9ticos comunes, incluyendo las enzimas que participan en la lectura, la escritura y el borrado de marcas epigen\u00e9ticas espec\u00edficas. Luego se describen los desarrollos recientes en la comprensi\u00f3n de c\u00f3mo el EIV produce cambios en el epigenoma, lo que se manifiesta -en modelos animales- en una mayor susceptibilidad a anormalidades similares a la depresi\u00f3n. Se finaliza destacando la necesidad de futuros estudios que potencialmente permitan utilizar la comprensi\u00f3n de los cambios epigen\u00e9ticos relacionados con el EIV para el desarrollo de muy necesarias nuevas estrategias terap\u00e9uticas y el descubrimiento de biomarcadores."
      ],
      "CopyrightInformation": "\u00a9 2019, AICH Servier Group\ufeffCopyright \u00a9 2019 AICH Servier Group. All rights reserved."
    },
    {
      "AbstractText": [
        "La d\u00e9pression, trouble psychiatrique destructeur, est provoqu\u00e9e par une association de pr\u00e9disposition g\u00e9n\u00e9tique et d\u2019\u00e9v\u00e9nements de vie, principalement l\u2019exposition au stress. Le stress de d\u00e9but de vie est particuli\u00e8rement connu pour laisser une \u00ab cicatrice \u00bb au cerveau, le rendant plus susceptible de d\u00e9velopper une d\u00e9pression ult\u00e9rieure par le biais de m\u00e9canismes \u00e9pig\u00e9n\u00e9tiques. Les processus \u00e9pig\u00e9n\u00e9tiques entra\u00eenent des modifications de l\u2019expression g\u00e9nique qui ne sont pas dues \u00e0 des changements de s\u00e9quence ADN mais qui apparaissent par modulation des modifications de la chromatine, par m\u00e9thylation de l\u2019ADN et par des ARN non codants. Nous analysons dans cet article les m\u00e9canismes \u00e9pig\u00e9n\u00e9tiques courants, dont les enzymes impliqu\u00e9es dans la lecture, l\u2019\u00e9criture et l\u2019effacement de marques \u00e9pig\u00e9n\u00e9tiques sp\u00e9cifiques. Ainsi que nous le d\u00e9crivons ensuite, des avanc\u00e9es r\u00e9centes nous permettent de comprendre comment le stress de d\u00e9but de vie modifie l\u2019\u00e9pig\u00e9nome en augmentant la susceptibilit\u00e9 aux anomalies de la d\u00e9pression dans les mod\u00e8les animaux. Nous en concluons que de nouvelles \u00e9tudes sont n\u00e9cessaires qui pourraient utiliser cette compr\u00e9hension des modifications \u00e9pig\u00e9n\u00e9tiques li\u00e9es au stress de d\u00e9but de vie pour d\u00e9velopper d\u2019indispensables nouvelles strat\u00e9gies th\u00e9rapeutiques et la d\u00e9couverte de biomarqueurs."
      ],
      "CopyrightInformation": "\u00a9 2019, AICH Servier Group\ufeffCopyright \u00a9 2019 AICH Servier Group. All rights reserved."
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "31949402",
  "DateCompleted": {
    "Year": "2020",
    "Month": "06",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2020",
    "Month": "06",
    "Day": "12"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.31887/DCNS.2019.21.4/enestler"
    ],
    "Journal": {
      "ISSN": "1958-5969",
      "JournalIssue": {
        "Volume": "21",
        "Issue": "4",
        "PubDate": {
          "Year": "2019",
          "Month": "Dec"
        }
      },
      "Title": "Dialogues in clinical neuroscience",
      "ISOAbbreviation": "Dialogues Clin Neurosci"
    },
    "ArticleTitle": "Unraveling the epigenetic landscape of depression: focus on early life stress\u2029.",
    "Pagination": {
      "StartPage": "341",
      "EndPage": "357",
      "MedlinePgn": "341-357"
    },
    "Abstract": {
      "AbstractText": [
        "Depression is a devastating psychiatric disorder caused by a combination of genetic predisposition and life events, mainly exposure to stress. Early life stress (ELS) in particular is known to \"scar\" the brain, leading to an increased susceptibility to developing depression later in life via epigenetic mechanisms. Epigenetic processes lead to changes in gene expression that are not due to changes in DNA sequence, but achieved via modulation of chromatin modifications, DNA methylation, and noncoding RNAs. Here we review common epigenetic mechanisms including the enzymes that take part in reading, writing, and erasing specific epigenetic marks. We then describe recent developments in understanding how ELS leads to changes in the epigenome that are manifested in increased susceptibility to depression-like abnormalities in animal models. We conclude with highlighting the need for future studies that will potentially enable the utilisation of the understanding of epigenetic changes linked to ELS for the development of much-needed novel therapeutic strategies and biomarker discovery.\u2029."
      ],
      "CopyrightInformation": "\u00a9 2019, AICH Servier Group\ufeffCopyright \u00a9 2019 AICH Servier Group. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, US."
          }
        ],
        "LastName": "Torres-Berr\u00edo",
        "ForeName": "Ang\u00e9lica",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Author affiliations: Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, US."
          }
        ],
        "LastName": "Issler",
        "ForeName": "Orna",
        "Initials": "O"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Author affiliations: Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, US."
          }
        ],
        "LastName": "Parise",
        "ForeName": "Eric M",
        "Initials": "EM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Author affiliations: Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, US."
          }
        ],
        "LastName": "Nestler",
        "ForeName": "Eric J",
        "Initials": "EJ"
      }
    ],
    "GrantList": [
      {
        "GrantID": "P50 MH096890",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 MH051399",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Dialogues Clin Neurosci",
    "NlmUniqueID": "101238198",
    "ISSNLinking": "1294-8322"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "DNA Methylation"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Epigenomics"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Genetic Predisposition to Disease"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Stress, Psychological"
    }
  ]
}